Utilities and other high yielding sectors are reaching overbought levels, so investors may want to rotate into biotechs, says TheStreet's Jim Cramer. Cramer said packaged-goods companies and REITs have reached their 'outer-limits' and the money in those areas may gravitate to biotech stocks that have been pressured in the past year. Cramer highlighted a bullish call by RealMoney technical strategist Bruce Kamich on Regeneron (REGN) , saying the stock is poised for a major breakout. Regeneron reports quarterly earnings on Thursday before the open.
More from Video
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Is Renewable Energy the Defensive Stock Opportunity You're Missing
AMSC CEO discusses that and China challenges.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.